Company intelligence / Profile preview

Coramed Technologies

Niles, Illinois, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

Coramed Technologies developed and commercialized point-of-care instruments for real-time monitoring of patient hemostasis. Its core technologies include the CORA system and the TEG 6000 series analyzers. The intellectual property underlying its main products was acquired by Haemonetics for use in hospital and laboratory settings. The company filed at least eight patents related to blood tests and coagulation systems. Clinical results are not detailed in public sources.

Therapeutic areas: Hematology
Modalities: Device (point-of-care hemostasis analyzer)
Industry: Physiological Monitoring

Partnerships

Haemonetics (licensed/acquired IP for hospital/lab use)

Beyond the preview

Go deeper on Coramed Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coramed Technologies.

Explore the full profile